Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | SLC22A1 | O15245 | 3/20 | 0.33 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | DNM1 | Q05193 | 5/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2683502 | 0.88 | TSHR (0.50) | TSHRLMNATHRBALDH1A1SLC22A1 | |
| SCHEMBL8643394 | 0.85 | TSHR (0.57) | TSHRLMNATHRBALDH1A1SLC22A1 | |
| SCHEMBL14889479 | 0.82 | TSHR (0.38) | TSHRLMNATHRBALDH1A1TDP1 | |
| SCHEMBL9015891 | 0.77 | TSHR (0.33) | TSHRLMNATHRBALDH1A1TDP1 | |
| SCHEMBL135552 | 0.75 | TSHR (0.46) | TSHRLMNATHRBALDH1A1TDP1 | |
| SCHEMBL28438742 | 0.75 | TSHR (0.46) | TSHRLMNATHRBALDH1A1TDP1 | |
| SCHEMBL5953560 | 0.72 | — | — | |
| Hydrochloric Acid SCHEMBL336735 | 0.72 | TSHR (0.43) | TSHRLMNATHRBALDH1A1TDP1 | |
| Water SCHEMBL3700992 | 0.72 | TSHR (0.43) | TSHRLMNATHRBALDH1A1TDP1 | |
| SCHEMBL2541194 | 0.72 | TSHR (0.43) | TSHRLMNATHRBALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 870 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4683914-A2 | RADIOLABELED FIBROBLAST ACTIVATION PROTEIN INHIBITORS AND METHODS OF MAKING SAME | Regents of the University of Michigan (US) | 2026-01-28 | — | — | EP | claimed |
| WO-2024197111-A2 | RADIOLABELED FIBROBLAST ACTIVATION PROTEIN INHIBITORS AND METHODS OF MAKING SAME | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-09-26 | — | — | WO | claimed |
| EP-2346815-B1 | METHOD FOR PRODUCING COMPOUNDS INCLUDING NITRILE FUNCTIONS | INVISTA Technologies S à r l (CH) | 2016-04-20 | — | — | EP | claimed |
| US-20160009638-A1 | PROCESS FOR PRODUCING COMPOUNDS COMPRISING NITRILE FUNCTIONS | INVISTA NORTH AMERICA S.A R.L. (US) | 2016-01-14 | — | — | US | claimed |
| US-9174207-B2 | Process for producing compounds comprising nitrile functions | INVISTA NORTH AMERICA S.A.R.L. (US) | 2015-11-03 | — | — | US | claimed |
| US-20120004440-A1 | PROCESS FOR PRODUCING COMPOUNDS COMPRISING NITRILE FUNCTIONS | INVISTA NORTH AMERICA SARL | 2012-01-05 | — | — | US | claimed |
| EP-2382186-A1 | METHOD FOR PRODUCING COMPOUNDS INCLUDING NITRILE FUNCTIONS | Rhodia Opérations (FR) | 2011-11-02 | — | — | EP | claimed |
| EP-2346815-A1 | METHOD FOR PRODUCING COMPOUNDS INCLUDING NITRILE FUNCTIONS | Rhodia Opérations (FR) | 2011-07-27 | — | — | EP | claimed |
| WO-2010086246-A1 | METHOD FOR PRODUCING COMPOUNDS INCLUDING NITRILE FUNCTIONS | RHODIA OPERATIONS (FR) | 2010-08-05 | — | — | WO | claimed |
| WO-2010046226-A1 | METHOD FOR PRODUCING COMPOUNDS INCLUDING NITRILE FUNCTIONS | RHODIA OPERATIONS (FR) | 2010-04-29 | — | — | WO | claimed |
| US-12637398-B2 | Radiohalogen prosthetic moieties and radiolabeled biomolecules | DUKE UNIVERSITY (US) | 2026-05-26 | — | — | US | disclosed |
| WO-2026107349-A1 | HETEROCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASES | ANTARES THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| WO-2026101724-A1 | AMINO PYRIMIDINE AND AMINO TRIAZINE ANALOGS FOR TREATING CANCER | NEREID THERAPEUTICS INCORPORATED (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-4739683-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | Janssen Pharmaceutica NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| US-20260125398-A1 | 5,6-FUSED BICYCLIC ALCOHOL COMPOUNDS AS 15-PROSTAGLANDIN DEHYDROGENASE MODULATORS | AMGEN INC. (US) | 2026-05-07 | — | — | US | disclosed |
| US-5420138-A | Antivasoconstriction compounds and cardiovascular disorders | ROUSSEL-UCLAF (FR) | 1995-05-30 | — | — | US | disclosed |
| EP-0636129-A1 | INDOLE DERIVATIVES AS 5-HT1-LIKE AGONISTS | Pfizer Limited (GB) | 1995-02-01 | — | — | EP | disclosed |
| EP-0592779-A1 | Process for the preparation of distannanes | Witco GmbH (DE) | 1994-04-20 | — | — | EP | disclosed |
| WO-1993021178-A1 | INDOLE DERIVATIVES AS 5-HT1-LIKE AGONISTS | PFIZER LIMITED (GB) | 1993-10-28 | — | — | WO | disclosed |
| WO-1993008799-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009638-A1 | PROCESS FOR PRODUCING COMPOUNDS COMPRISING NITRILE FUNCTIONS | NIT2, NANP, LPO | TSHR 4258/4885LMNA 3923/4885THRB 4856/4885 |
| US-20120004440-A1 | PROCESS FOR PRODUCING COMPOUNDS COMPRISING NITRILE FUNCTIONS | NANP, NIT2, LPO | TSHR 4256/4885LMNA 4026/4885THRB 4857/4885 |
| US-12637398-B2 | Radiohalogen prosthetic moieties and radiolabeled biomolecules | CD47, KLK3, SHBG | TSHR 27/4885LMNA 4581/4885THRB 111/4885 |
| US-20260125398-A1 | 5,6-FUSED BICYCLIC ALCOHOL COMPOUNDS AS 15-PROSTAGLANDIN DEHYDROGENASE MODULATORS | ADH1A, ADH5, ADH1C | TSHR 1784/4885LMNA 2530/4885THRB 1176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.